Cargando…
The diagnostic journey for patients with late-onset GM2 Gangliosidoses
Late-onset forms of GM2 gangliosidosis―mainly, Tay-Sachs disease and Sandhoff disease―are under-recognized in clinical practice. In these rare lysosomal storage disorders, deficiency of β-hexosaminidase A results in excessive accumulation of GM2 ganglioside primarily within neurons, leading to cell...
Autores principales: | Lopshire, Mariah C., Tifft, Cynthia, Burns, John, Gould, Rebecca, Zheng, Riliang, Batsu, Isabela |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10694732/ http://dx.doi.org/10.1016/j.ymgmr.2023.101014 |
Ejemplares similares
-
The GM2 gangliosidoses: Unlocking the mysteries of pathogenesis and treatment
por: Toro, Camilo, et al.
Publicado: (2021) -
Thymic Alterations in GM2 Gangliosidoses Model Mice
por: Kanzaki, Seiichi, et al.
Publicado: (2010) -
GM2 Gangliosidoses: Clinical Features, Pathophysiological Aspects, and Current Therapies
por: Leal, Andrés Felipe, et al.
Publicado: (2020) -
Chitotriosidase as a biomarker for gangliosidoses
por: Kim, Sarah, et al.
Publicado: (2021) -
Plasma neurofilament light, glial fibrillary acidic protein and lysosphingolipid biomarkers for pharmacodynamics and disease monitoring of GM2 and GM1 gangliosidoses patients
por: Welford, Richard W.D., et al.
Publicado: (2022)